Insights into Migraine Treatments

Massimo Filippi, MD, is Full Professor of Neurology at Vita-Salute San Raffaele University, Director of the Residency School in Neurology, President of the Bacherlor’s Degree in Physiotherapy, Chair of the Neurology and Neurorehabilitation Units, Director of the MS Center, Director of the Neurophysiology Service, and Director of the Neuroimaging Research Unit at IRCCS Scientific Institute San Raffaele, Milan. His research activity has always focused on the definition of the mechanisms underlying various neurological conditions, including multiple sclerosis, neurodegenerative disorders, and migraine. As Director of the of the Neuroimaging Research Unit, he coordinated the MRI acquisition and analysis of several large-scale international MRI-monitored trials of multiple sclerosis. He is member of various national and international Scientific Societies and Boards and for some of them, he holds or has held institutional roles. He is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Radiology, and Neurological Sciences. Roberta Messina, MD, PhD, is a neurologist with expertise in the evaluation of headache patients, as well as in the analysis of MRI. She is a post-doctoral researcher at the Neuroimaging Research Unit and a headache specialist at the Headache Center at IRCCS Scientific Institute San Raffaele, Milan. Her main interests are studying biomarkers of headache patients´ responses to treatments, and the use of MRI techniques in primary headache disorders. She has applied MRI techniques to study the mechanisms underlying migraine pathophysiology, yielding new insights into brain alterations associated with migraine. She has collaborated in national and international studies assessing the efficacy, safety, and mechanisms of actions of novel treatments employed for migraine prevention. She is the Italian representative in the Juniors Committee of the International Headache Society and part of its Education Committee. She is on the Editorial Board of the Journal of Headache and Pain.

• 1. Clinical manifestations of migraine2. Why, when, and how to treat migraine patients?3. Acute treatments: nonsteroidal anti-inflammatory drugs, ergot alkaloids, triptans, and ditans4. Acute treatments: neuromodulation and peripheral nerve blocks5. Oral preventive treatments: antidepressants, antihypertensives, anticonvulsants, betablockers, and calcium channel blockers6. Preventive treatments: onabotulinumtoxinA and peripheral nerve blocks7. Nonpharmacological approaches in migraine prevention: neuromodulation, nutraceuticals, and behavioral approaches8. Why target the calcitonin gene-related peptide pathway: Receptors, intracellular pathways, and its role in migraine pathophysiology9. Gepants10. Anti-CGRP monoclonal antibodies11. Biomarkers of treatment response12. Migraine treatments: what have we learned from neuroimaging?13. Migraine treatments: what have we learned from neurophysiology?14. Treatments to use in special circumstances: children, pregnancy, elderly15. Unmet needs and future perspectives